Androgenetic Alopecia in Women: Everything You Need to Know

What Is Androgenetic Alopecia in Women?

Androgenetic alopecia (AGA) is a genetically determined, hormone-sensitive form of progressive hair loss that is the most common cause of alopecia in both men and women. When it occurs in women, it is also called female pattern hair loss (FPHL). The terms are interchangeable — both describe the same underlying biological condition.

"Andro-" refers to androgens, the hormones that interact with genetically susceptible hair follicles to shorten their growth cycles. "-Genetic" refers to the inherited predisposition that determines which follicles are susceptible. Neither factor alone causes the condition — both must be present.

In men, androgenetic alopecia is immediately recognisable: receding temples, balding vertex, the classic Norwood-Hamilton pattern. In women, the picture is quieter and more diffuse, which is why it is so frequently missed or misattributed. The frontal hairline is usually preserved, a widening part is often the first sign, and outright baldness is rare. But the hair loss is real, progressive, and emotionally significant.

The Biology: How Androgens Miniaturise Hair Follicles

Understanding the mechanism helps clarify what treatment does — and does not — achieve.

The Androgen-DHT-Follicle Axis

Testosterone circulates in the bloodstream. In androgen-sensitive scalp follicles, the enzyme 5-alpha-reductase Type 2 converts testosterone into dihydrotestosterone (DHT) — a more potent androgen with a stronger affinity for androgen receptors. When DHT binds androgen receptors within the hair follicle's dermal papilla cells, it triggers a cascade of gene expression changes that:

1. Shortens the anagen (growth) phase from several years to just months per cycle
2. Prolongs the telogen (resting/shedding) phase relative to growth
3. Progressively miniaturises the follicle — each successive hair produced is thinner, shorter, and less pigmented than its predecessor

Over years, this process transforms robust terminal hairs (thick, pigmented, visible) into vellus-like fibers (fine, nearly colorless, barely emergent) — and eventually into atrophied follicles incapable of producing visible hair at all.

Why Women Are Different from Men

Women have lower circulating androgen levels, lower concentrations of 5-alpha-reductase in scalp tissue, and lower androgen receptor density in hair follicles than men. This explains why:

• Women's hair loss is more diffuse and rarely progresses to complete baldness
• The frontal hairline — which has low androgen receptor density — is typically spared
• FPHL tends to develop more slowly and less severely than male pattern AGA
• Women respond differently (and sometimes less robustly) to anti-androgen treatments

Critically, most women with AGA have normal serum androgen levels. The driver is the follicle's genetic sensitivity to androgens that are present at entirely normal concentrations, not an excess of androgens. Only a minority have true hyperandrogenism (elevated serum androgens), and this minority requires additional investigation.

The Genetic Architecture

AGA is polygenic — controlled by multiple genes, not a single hereditary locus. Genes can be inherited from either parent. This explains the clinical observation that FPHL can appear with no family history on the mother's side, or can skip generations, or can manifest differently in siblings despite the same parents. The androgen receptor gene on the X chromosome carries particular influence, but it is not the sole determinant.

Who Develops It and When

Androgenetic alopecia can begin at any age after puberty — sometimes as early as the late teens or early twenties. Peak onset in women, however, follows two age peaks:

• Peri-reproductive years (late 20s–30s): Early-onset AGA, often associated with PCOS or other hormonal conditions
• Perimenopausal and postmenopausal years: The most common presentation. Estrogen's partial protective effect on follicles diminishes after menopause, unmasking genetic AGA that had been subclinical

Prevalence by age in women:

• Age 29 and under: approximately 12%
• By age 50: approximately 40%
• By age 79: more than 50%
• Fewer than 45% of women maintain full hair density throughout their lifetime

Ethnicity also influences prevalence: Caucasian women are most frequently affected, followed by Asian women, with lower rates in African American and Indigenous populations.

Clinical Presentation: What to Look For

The Classic (Ludwig) Pattern

The most common presentation in women is diffuse thinning of the central scalp:

• Widening of the center part line — often the earliest change women notice in photographs
• Decreased density across the crown and top of the scalp — the parting looks sparse; more scalp is visible under bright light
• Frontal hairline preserved — this is the key feature that distinguishes AGA from frontal fibrosing alopecia and from typical male pattern baldness
• Temporal recession is sometimes present but is not the dominant finding
• Hair calibre variability — within affected zones, a mix of miniaturised (fine, short) and normal-calibre hairs

The Christmas Tree (Olsen) Pattern

Some women show a triangular pattern of thinning that is widest at the anterior scalp and narrows toward the vertex — named for its resemblance to an inverted Christmas tree when the part is widened and examined from above. This pattern tends to have more frontal involvement.

Diffuse Pattern With Shedding

Women with AGA sometimes present primarily as increased shedding — noticing excessive hair on the pillow, shower drain, or brush — rather than a clearly visible thinning zone. This presentation overlaps significantly with telogen effluvium and can be diagnostically challenging. Dermoscopy typically reveals hair shaft diameter variability in the crown (a marker of miniaturisation) that confirms AGA as the underlying process.

Diagnosis

Clinical Assessment

A board-certified dermatologist or trichologist can diagnose AGA in most cases without invasive testing. The evaluation includes:

History:

• Onset and tempo of hair loss
• Family history (maternal and paternal)
• Menstrual and reproductive history
• Medication history (androgenic progestogens, anabolic steroids, spironolactone already on board)
• Recent stressors, illnesses, dietary changes, or weight loss

Examination:

• Distribution and density of hair loss (frontal hairline, crown, temples, occiput)
• Hair pull test — gentle extraction of 40–60 hairs. More than 6 telogen hairs extracted from the crown indicates active miniaturisation or associated shedding
• Assessment for signs of hyperandrogenism: acne, hirsutism, androgenic changes

Dermoscopy (Trichoscopy)

Scalp dermoscopy at 20–70× magnification has become standard practice for diagnosing and staging AGA. Key findings:

• Diameter variability: Greater than 20% of observed hairs showing significant calibre variation — the most reliable dermoscopic marker of AGA
• Vellus hair increase: Fine, short, barely pigmented hairs outnumbering terminal hairs in affected zones
• Peripilar sign: A yellowish-brown halo around follicular ostia, representing perifollicular inflammation
• Single-hair follicular units: In more advanced disease, follicular units that normally contain 2–4 hairs are represented by single thin hairs

Laboratory Testing

Not all women with AGA require blood tests, but they are appropriate when:

• Onset is before age 30 or 35
• Signs of hyperandrogenism are present (irregular periods, hirsutism, acne, unexplained weight gain)
• The clinical picture is atypical or shedding is severe

Standard panel:

• Ferritin: The most sensitive iron marker. Low ferritin (below 30–40 μg/L) impairs the hair cycle and amplifies any underlying AGA
• TSH: Thyroid dysfunction (both hypo- and hyperthyroidism) causes diffuse telogen shedding that can obscure or worsen AGA
• Free testosterone and DHEAS: Elevated levels indicate hyperandrogenism requiring investigation for PCOS, adrenal disorders, or androgen-secreting tumors
• Full blood count: Anemia as a contributing factor

Scalp Biopsy

Reserved for diagnostically uncertain cases. Horizontal sectioning of two 4-mm punch biopsies (one from the affected crown, one from an unaffected control site such as the occiput) is the gold standard:

• Terminal-to-vellus hair ratio below 4:1 is diagnostic of AGA
• Ratio of 4:1 to 8:1 suggests AGA with overlapping telogen effluvium
• Inflammatory infiltrate around the follicle isthmus may be seen in some cases

Differential Diagnosis

Several conditions can mimic AGA in women and must be distinguished:

AGA and telogen effluvium frequently co-exist, which can accelerate apparent AGA progression and makes diagnosis complex. Treating any co-existing deficiencies is important regardless.

Treatment

Topical Minoxidil

Topical minoxidil remains the only FDA-approved pharmacological treatment for AGA in women. It acts as a potassium channel opener, prolonging the anagen phase and increasing dermal papilla blood flow. Both 2% solution (applied twice daily) and 5% foam (once daily) are approved.

Key clinical data:

• Pooled data from six randomised controlled trials show twice the rate of moderate-to-marked regrowth with minoxidil versus placebo
• Mean hair count improvement: approximately 13 hairs/cm² above placebo across multiple trials
• Approximately 40% of users see little or no meaningful benefit — the reasons are not fully understood but may relate to genetic differences in minoxidil metabolism
• A temporary increase in shedding during the first 2–8 weeks is common and expected — it reflects the transition of resting follicles into active growth; not a sign the treatment is failing

Practical guidance:

• Apply directly to the scalp (not the hair shaft) in the affected area
• Allow to dry before styling
• Use indefinitely — stopping reverses gains within 3–6 months
• Morning facial hypertrichosis (fine hair on forehead or cheeks) is the most common side effect with solution; switching to foam reduces this risk

Oral Minoxidil

Low-dose oral minoxidil (0.25–2.5 mg daily) is increasingly prescribed off-label for AGA in women. Clinical data are compelling:

• Hair density improvement of 20–27 hairs/cm² at 1 mg daily — numerically higher than topical applications in multiple comparisons
• Better tolerated by women who experience scalp irritation from topical vehicles or who find daily topical application impractical
• Most common side effects: hypertrichosis (body hair increase, 54%), headache, peripheral edema (9%)
• Co-prescribing low-dose spironolactone (25 mg) reduces edema risk
• Not FDA-approved for hair loss; requires physician prescription and periodic monitoring of blood pressure and electrolytes

Spironolactone

Spironolactone is an anti-aldosterone drug with anti-androgenic properties used at 25–200 mg daily for AGA in women. It competitively inhibits androgen receptors in the hair follicle, reducing follicular sensitivity to DHT.

Evidence:

• One RCT showed equivalent efficacy to cyproterone acetate (an anti-androgen unavailable in the US)
• Retrospective studies show approximately 44% of treated women achieve photographic improvement
• Approximately 88% experience either improvement or stabilisation of hair loss in biopsy-confirmed FPHL

Side effects: menstrual irregularity (particularly at higher doses), fatigue, dizziness, hyperkalaemia. Contraindicated in pregnancy — teratogenic to male fetuses. Reliable contraception is mandatory.

Finasteride

Finasteride inhibits 5-alpha-reductase, reducing DHT production. At 1 mg daily (the dose approved for men with AGA), finasteride showed no significant benefit over placebo in the largest multicentre double-blind RCT in postmenopausal women. This finding is often misunderstood as "finasteride doesn't work in women" — but evidence at 2.5–5 mg daily in uncontrolled studies shows 62–81% of women achieving photographic improvement. Higher doses remain off-label and are used selectively by dermatologists in appropriate candidates.

Contraindicated in women of childbearing potential (teratogenic; causes feminisation of male fetuses). Postmenopausal women may use it under dermatologist supervision.

Dutasteride

Dutasteride inhibits both Type 1 and Type 2 5-alpha-reductase (finasteride inhibits only Type 2), theoretically offering more complete DHT suppression. Evidence in women is limited to small uncontrolled series. It carries the same teratogenic risk as finasteride.

Platelet-Rich Plasma (PRP)

PRP delivers a concentrated dose of autologous growth factors (including PDGF, VEGF, and IGF-1) to the scalp via injection. Growth factors stimulate follicular stem cells and may extend the anagen phase. A systematic review and meta-analysis found average improvements of approximately 36.8 hairs/cm² in density. However, PRP studies are highly heterogeneous in preparation technique, injection protocol, and follow-up duration. Multiple sessions (typically 3–4 initially, then every 3–6 months) are required. Cost per session ranges from several hundred to over a thousand US dollars, and it is not FDA-approved for AGA.

Low-Level Laser Therapy (LLLT)

Home-use laser combs and caps emitting red light at 650 nm are FDA-cleared (as medical devices, not drugs) for AGA. Proposed mechanism: photobiomodulation increasing follicular metabolic activity. RCTs show modest but measurable hair count improvements (~17 hairs/cm²) versus sham devices; subjective patient assessment shows less convincing improvement. LLLT is low-risk and may serve as an adjunct to pharmacological treatment.

Hair Transplantation

Follicular unit extraction (FUE) or transplantation (FUT) can be highly effective for women with AGA — but candidate selection is critical. The ideal candidate has:

• Adequate donor density in the occipital scalp (which is androgen-insensitive and unaffected by AGA)
• Stable AGA on medical treatment
• Realistic expectations (transplanted hairs are permanent, but native existing hairs may continue to miniaturise without treatment)

Women with diffuse AGA across the entire scalp — including the donor zone — are poor candidates for transplantation because donor hairs may be affected by AGA and eventually miniaturise after transplantation.

Living With Androgenetic Alopecia

AGA is a chronic condition. While treatment can slow or partially reverse progression, it does not cure the underlying genetic predisposition. Accepting this reality while taking proactive steps toward what is manageable produces the best outcomes.

Practical strategies alongside medical treatment:

• Camouflage products: Hair fibers (keratin-based), scalp concealers, and color-matched dry shampoos can provide immediate visual improvement
• Volumising styling: Avoiding tight hairstyles, using lightweight volumising products, and strategic parting can significantly improve appearance
• Nutritional support: Ensuring adequate protein, iron, zinc, and biotin intake supports overall hair health, although supplementation beyond deficiency correction is not proven to benefit AGA
• Psychological support: The emotional impact of hair loss is clinically significant. Support groups, counselling, and cognitive behavioral therapy can be valuable alongside medical treatment

When to Seek Evaluation

See a dermatologist if you notice:

• A center part that is visibly wider than it used to be
• Increasing scalp visibility on the crown under normal lighting
• A ponytail that is measurably thinner or smaller in circumference
• Finding significantly more shed hairs than previously on brushes, bedding, or in the shower drain
• Hair loss accompanied by irregular periods, unexplained weight gain, acne, or facial hair growth
• Hair loss following menopause, pregnancy, or stopping hormonal contraception

Early diagnosis maximizes the window for effective treatment. Follicles that are miniaturising can often be stabilized; follicles that have completely atrophied cannot be recovered with any currently available medical therapy.